• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 144 filed by Centessa Pharmaceuticals plc

    11/17/25 4:03:16 PM ET
    $CNTA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CNTA alert in real time by email
    Form 144 Filer Information UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Form 144

    NOTICE OF PROPOSED SALE OF SECURITIES
    PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

    FORM 144

    144: Filer Information

    Filer CIK
    0001863418
    Filer CCC
    XXXXXXXX
    Is this a LIVE or TEST Filing? Radio button checked LIVE Radio button not checked TEST

    Submission Contact Information

    Name
    Phone
    E-Mail Address

    144: Issuer Information

    Name of Issuer
    Centessa Pharmaceuticals plc
    SEC File Number
    001-40445
    Address of Issuer
    3RD FLOOR
    1 ASHLEY ROAD
    ALTRINCHAM, CHESHIRE
    UNITED KINGDOM
    WA14 2DT
    Phone
    44 7391 789784
    Name of Person for Whose Account the Securities are To Be Sold
    Bush Tia L
    See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

    Relationship to Issuer
    Officer

    144: Securities Information

    Title of the Class of Securities To Be SoldName and Address of the BrokerNumber of Shares or Other Units To Be SoldAggregate Market ValueNumber of Shares or Other Units OutstandingApproximate Date of SaleName the Securities Exchange
    Common
    UBS Financial Services Inc.
    11 Madison Ave.
    4th Floor
    New York � NY � 10010
    400001120000.0013444783611/17/2025
    NASDAQ


    Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

    144: Securities To Be Sold

    Title of the ClassDate you AcquiredNature of Acquisition TransactionName of Person from Whom AcquiredIs this a Gift?Date Donor AcquiredAmount of Securities AcquiredDate of PaymentNature of Payment *
    Common11/17/2025Exercise of Stock OptionsIssuerCheckbox not checked4000011/17/2025Cash

    * If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



    Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

    144: Securities Sold During The Past 3 Months

    Name and Address of SellerTitle of Securities SoldDate of SaleAmount of Securities SoldGross Proceeds
    Tia Bush
    3RD FLOOR
    1 ASHLEY ROAD
    ALTRINCHAM, CHESHIRE � X0 � WA14 2DT
    Common09/09/202524792495840.00
    Tia Bush
    3RD FLOOR
    1 ASHLEY ROAD
    ALTRINCHAM, CHESHIRE � X0 � WA14 2DT
    Common09/10/202525000550000.00
    Tia Bush
    3RD FLOOR
    1 ASHLEY ROAD
    ALTRINCHAM, CHESHIRE � X0 � WA14 2DT
    Common09/24/202535000840000.00
    Tia Bush
    3RD FLOOR
    1 ASHLEY ROAD
    ALTRINCHAM, CHESHIRE � X0 � WA14 2DT
    Common11/12/2025400001040000.00

    144: Remarks and Signature

    Remarks
    The transactions reported herein were effected pursuant to a Rule 10b5-1 trading plan.
    Date of Notice
    11/17/2025
    Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1
    09/14/2024

    ATTENTION:

    The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
    Signature
    /s/ UBS Financial Services Inc, as attorney-in-fact for Tia Bush

    ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

    Get the next $CNTA alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CNTA

    DatePrice TargetRatingAnalyst
    10/28/2025$35.00Overweight
    Stephens
    9/3/2025$31.00Overweight
    Wells Fargo
    8/29/2025$40.00Outperform
    Oppenheimer
    7/21/2025$30.00Buy
    Truist
    5/28/2025$35.00Buy
    Needham
    5/8/2025$30.00Buy
    Chardan Capital Markets
    3/31/2025$38.00Overweight
    Piper Sandler
    1/7/2025Buy
    TD Cowen
    More analyst ratings

    $CNTA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    General Counsel Hussain Iqbal J exercised 6,000 units of Ordinary Shares at a strike of $5.84 and sold $165,835 worth of Ordinary Shares (6,000 units at $27.64) (SEC Form 4)

    4 - Centessa Pharmaceuticals plc (0001847903) (Issuer)

    11/18/25 4:18:17 PM ET
    $CNTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Technology & Quality Ofc Bush Tia L exercised 40,000 units of Ordinary Shares at a strike of $9.42 and sold $1,120,000 worth of Ordinary Shares (40,000 units at $28.00) (SEC Form 4)

    4 - Centessa Pharmaceuticals plc (0001847903) (Issuer)

    11/18/25 4:17:11 PM ET
    $CNTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Technology & Quality Ofc Bush Tia L exercised 40,000 units of Ordinary Shares at a strike of $9.42 and sold $1,040,000 worth of Ordinary Shares (40,000 units at $26.00) (SEC Form 4)

    4 - Centessa Pharmaceuticals plc (0001847903) (Issuer)

    11/13/25 5:02:28 PM ET
    $CNTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CNTA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Centessa Pharmaceuticals Announces Pricing of $250,000,000 Public Offering of American Depositary Shares

    BOSTON and LONDON, Nov. 11, 2025 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (NASDAQ:CNTA), a clinical-stage pharmaceutical company, today announced the pricing of an underwritten public offering of 11,627,907 American Depositary Shares ("ADSs"), each representing one ordinary share, at a price to the public of $21.50 per ADS. The aggregate gross proceeds to Centessa from this offering are expected to be approximately $250 million, before deducting underwriting discounts and commissions and offering expenses payable by Centessa. All ADSs sold in the offering were offered by Centessa. The offering is expected to close on or about November 14, 2025, subject to customary closing conditio

    11/11/25 8:40:00 PM ET
    $CNTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Centessa Pharmaceuticals Announces Proposed Public Offering of American Depositary Shares

    BOSTON and LONDON, Nov. 11, 2025 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (NASDAQ:CNTA), a clinical-stage pharmaceutical company, today announced that it has commenced an underwritten public offering of American Depositary Shares ("ADSs"), each representing one ordinary share. All of the ADSs are being offered by Centessa. In addition, Centessa intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the ADSs offered in the public offering. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. Jefferies, Le

    11/11/25 4:00:00 PM ET
    $CNTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences

    BOSTON and LONDON, Nov. 07, 2025 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (NASDAQ:CNTA), a clinical-stage pharmaceutical company that aims to discover and develop transformational medicines for patients, today announced that members of its management team will participate in the following investor conferences: Event: Guggenheim 2nd Annual Healthcare Innovation ConferenceDate: Wednesday, November 12, 2025Fireside Chat: 10:30 AM ET Event: Jefferies Global Healthcare Conference in LondonDate: Tuesday, November 18, 2025Fireside Chat: 2:00 PM GMT/ 9:00 AM ET Event: 37th Annual Piper Sandler Healthcare ConferenceDate: Tuesday, December 2, 2025Fireside Chat: 3:00 PM ET Event: 8th Annu

    11/7/25 8:00:00 AM ET
    $CNTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CNTA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Stephens initiated coverage on Centessa Pharmaceuticals with a new price target

    Stephens initiated coverage of Centessa Pharmaceuticals with a rating of Overweight and set a new price target of $35.00

    10/28/25 8:03:12 AM ET
    $CNTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Wells Fargo initiated coverage on Centessa Pharmaceuticals with a new price target

    Wells Fargo initiated coverage of Centessa Pharmaceuticals with a rating of Overweight and set a new price target of $31.00

    9/3/25 8:36:52 AM ET
    $CNTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Oppenheimer resumed coverage on Centessa Pharmaceuticals with a new price target

    Oppenheimer resumed coverage of Centessa Pharmaceuticals with a rating of Outperform and set a new price target of $40.00

    8/29/25 8:20:12 AM ET
    $CNTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CNTA
    SEC Filings

    View All

    SEC Form 144 filed by Centessa Pharmaceuticals plc

    144 - Centessa Pharmaceuticals plc (0001847903) (Subject)

    11/17/25 4:03:16 PM ET
    $CNTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SCHEDULE 13G filed by Centessa Pharmaceuticals plc

    SCHEDULE 13G - Centessa Pharmaceuticals plc (0001847903) (Subject)

    11/14/25 9:05:31 AM ET
    $CNTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Centessa Pharmaceuticals plc

    SCHEDULE 13G/A - Centessa Pharmaceuticals plc (0001847903) (Subject)

    11/13/25 9:06:31 AM ET
    $CNTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CNTA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Goyal Arjun bought $5,865,242 worth of Ordinary Shares (462,585 units at $12.68) (SEC Form 4)

    4 - Centessa Pharmaceuticals plc (0001847903) (Issuer)

    5/19/25 5:49:01 PM ET
    $CNTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CNTA
    Leadership Updates

    Live Leadership Updates

    View All

    Centessa Pharmaceuticals Announces Appointment of Stephen Kanes, MD PhD, as Chief Medical Officer

    BOSTON and LONDON, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (NASDAQ:CNTA), a clinical stage pharmaceutical company with a mission to discover, develop and ultimately deliver medicines that are transformational for patients, today announced the appointment of Stephen Kanes MD PhD, as Chief Medical Officer (CMO). Dr. Kanes is a neuropsychiatrist, with a career in neuroscience, clinical psychiatry, and neuroscience drug development spanning more than 30 years.  "Centessa is rapidly advancing a potential best-in-class and first-in-class portfolio of orexin receptor 2 (OX2R) agonists with a robust series of clinical milestones anticipated this year," said Saurabh Saha MD

    1/8/25 7:05:00 AM ET
    $CNTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Centessa Pharmaceuticals Strengthens Executive Leadership with Appointment of John Crowley CPA, as Chief Financial Officer and Gregory Weinhoff MD MBA, as Chief Business Officer

    BOSTON and LONDON, June 10, 2024 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (NASDAQ:CNTA), a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for patients, today announced that John Crowley CPA, has been appointed Chief Financial Officer, and Gregory Weinhoff MD MBA, former Chief Financial Officer, has been appointed to the newly created role of Chief Business Officer, effective June 10, 2024. "With all three of our core programs in the clinic, we believe we have solidified a strong foundation and are poised for our next exciting chapter as a company. To best position Centessa for this pivotal time, we've added key new talen

    6/10/24 7:00:00 AM ET
    $CNTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Centessa Pharmaceuticals Announces Additions to Senior Leadership Team

    BOSTON and LONDON, Oct. 03, 2023 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (NASDAQ:CNTA), a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for patients, today announced the appointment of April Dovholuk and Ellie Im, MD to Centessa's executive team as Senior Vice President of Development Operations and Senior Vice President of Clinical Development, Oncology, respectively. In these newly created roles, Ms. Dovholuk will lead both Centessa's global Clinical Trials and Development Operations teams, and Dr. Im will manage clinical development of the Company's Oncology programs based on the LockBody® technology platform. "We a

    10/3/23 8:00:00 AM ET
    $CNTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CNTA
    Financials

    Live finance-specific insights

    View All

    Centessa Pharmaceuticals Reports Financial Results for the Third Quarter of 2025 and Provides Update on Potential Best-in-Class Orexin Receptor 2 (OX2R) Agonist Program

    ORX750: Demonstrated potential best-in-class profile for treatment of narcolepsy type 1 (NT1), narcolepsy type 2 (NT2), and idiopathic hypersomnia (IH) in initial cohorts of ongoing Phase 2a study; Data mark first robust demonstration of oral OX2R agonist addressing wakefulness needs of patients across all three indications; Expect to initiate registrational program in Q1 2026ORX142: Phase 1 data support highly differentiated profile; Expect to initiate patient studies in Q1 2026 ORX489: Advancing in IND-enabling studies; Expect to initiate clinical studies in Q1 2026 BOSTON and LONDON, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (NASDAQ:CNTA), a clinical-stage pharmace

    11/5/25 7:00:00 AM ET
    $CNTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2025

    Advancing a broad, potential best-in-class orexin receptor 2 (OX2R) agonist franchise, with key data readouts expected this year ORX750 Phase 2a CRYSTAL-1 study for the treatment of narcolepsy type 1 (NT1), narcolepsy type 2 (NT2) and idiopathic hypersomnia (IH) on track with data expected in all three indications this year with first-in-class potential in NT2 and IH ORX142 Phase 1 clinical trial for the treatment of select neurological and neurodegenerative disorders underway with data in acutely sleep-deprived healthy volunteers expected this year ORX489 in IND-enabling studies for the treatment of neuropsychiatric disorders BOSTON and LONDON, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Cent

    8/12/25 7:00:26 AM ET
    $CNTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the First Quarter of 2025

    Advancing a broad, potential best-in-class orexin receptor 2 (OX2R) agonist franchise, with key data readouts expected this year ORX750 Phase 2a CRYSTAL-1 study for the treatment of narcolepsy type 1 (NT1), narcolepsy type 2 (NT2) and idiopathic hypersomnia (IH) on track with data expected across all three indications this year with first-in-class potential in NT2 and IHORX142 on track to initiate first-in-human studies for the treatment of neurological and neurodegenerative disorders with clinical data in acutely sleep-deprived healthy volunteers planned for this yearORX489 advancing in IND-enabling studies for the treatment of neuropsychiatric disorders BOSTON and LONDON, May 14, 20

    5/14/25 7:00:53 AM ET
    $CNTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CNTA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Centessa Pharmaceuticals plc

    SC 13G/A - Centessa Pharmaceuticals plc (0001847903) (Subject)

    11/14/24 5:43:48 PM ET
    $CNTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Centessa Pharmaceuticals plc

    SC 13G/A - Centessa Pharmaceuticals plc (0001847903) (Subject)

    11/14/24 4:20:32 PM ET
    $CNTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Centessa Pharmaceuticals plc (Amendment)

    SC 13G/A - Centessa Pharmaceuticals plc (0001847903) (Subject)

    2/14/24 5:37:34 PM ET
    $CNTA
    Biotechnology: Pharmaceutical Preparations
    Health Care